Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

Dysregulation of complement at the synapse in P301S mice and human tauopathies.

Acta neuropathologica communications·2026
Same author

Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries.

Therapeutic advances in neurological disorders·2026
Same author

MOGAD in South Wales: Diagnostic Evolution and Disease Epidemiology.

European journal of neurology·2026
Same author

Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long COVID.

Immunology·2026
Same author

Genetic subtypes associated with multiple sclerosis severity and response to treatment.

Journal of neurology, neurosurgery, and psychiatry·2026

Related Experiment Video

Updated: Jun 13, 2026

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
08:47

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues

Published on: May 8, 2016

Elevated plasma C4a levels in multiple sclerosis correlate with disease activity.

Gillian Ingram1, Svetlana Hakobyan, Neil P Robertson

  • 1Department of Neurosciences, Cardiff University, Heath Park, Cardiff, UK.

Journal of Neuroimmunology
|April 23, 2010
PubMed
Summary

Complement activation, indicated by elevated C4a levels in cerebrospinal fluid (CSF) and plasma, is implicated in multiple sclerosis (MS) pathogenesis, suggesting both central and systemic disease components.

More Related Videos

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
09:01

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Related Experiment Videos

Last Updated: Jun 13, 2026

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
08:47

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues

Published on: May 8, 2016

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
09:01

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Area of Science:

  • Immunology
  • Neurology
  • Complement System

Background:

  • The complement system, a crucial part of innate immunity, is increasingly recognized for its role in autoimmune diseases.
  • Complement component C4 (C4) and its activation fragment C4a have been associated with disease activity in multiple sclerosis (MS).

Purpose of the Study:

  • To investigate the correlation between plasma C4, and plasma and cerebrospinal fluid (CSF) C4a levels with clinical disease status in MS patients.
  • To determine if complement activation is indicative of intrathecal or systemic processes in MS.

Main Methods:

  • Quantitative analysis of plasma C4, plasma C4a, and CSF C4a levels.
  • Correlation of complement fragment levels with clinical parameters in a cohort of MS patients and healthy controls.

Main Results:

  • Cerebrospinal fluid C4a levels were significantly elevated in MS patients compared to controls.
  • Plasma C4a levels were elevated during acute relapse and decreased over a two-month period.
  • Plasma C4 levels showed a non-significant trend towards elevation in MS patients.

Conclusions:

  • These findings demonstrate both intrathecal and systemic activation of the complement system in MS.
  • Elevated C4a in CSF and plasma supports the role of complement activation in MS pathogenesis.
  • The results suggest a significant systemic component contributing to the disease process in MS.